 Ann Kulungowski
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 8 | 2022 | 47 | 3.250 |
Why?
| | Lymphatic Abnormalities | 3 | 2020 | 18 | 1.700 |
Why?
| | Sclerotherapy | 2 | 2018 | 18 | 1.140 |
Why?
| | Secondary Prevention | 2 | 2018 | 220 | 1.030 |
Why?
| | Wounds, Penetrating | 2 | 2023 | 67 | 0.920 |
Why?
| | Hemangioma | 5 | 2016 | 38 | 0.850 |
Why?
| | Surgical Wound | 1 | 2023 | 18 | 0.840 |
Why?
| | Neutropenia | 1 | 2023 | 122 | 0.810 |
Why?
| | Chylous Ascites | 1 | 2022 | 6 | 0.810 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2022 | 18 | 0.810 |
Why?
| | Chylothorax | 1 | 2022 | 11 | 0.810 |
Why?
| | Respiration Disorders | 1 | 2022 | 68 | 0.770 |
Why?
| | Wounds, Nonpenetrating | 3 | 2019 | 246 | 0.750 |
Why?
| | Intestines | 2 | 2022 | 324 | 0.680 |
Why?
| | Surgery Department, Hospital | 2 | 2016 | 22 | 0.650 |
Why?
| | Pediatric Emergency Medicine | 1 | 2019 | 16 | 0.640 |
Why?
| | Hypovolemia | 1 | 2019 | 12 | 0.640 |
Why?
| | Vertebral Artery | 1 | 2019 | 25 | 0.640 |
Why?
| | Carotid Artery Injuries | 1 | 2019 | 42 | 0.630 |
Why?
| | Surgeons | 1 | 2022 | 235 | 0.620 |
Why?
| | Liver Neoplasms | 5 | 2015 | 504 | 0.620 |
Why?
| | Doxycycline | 1 | 2018 | 53 | 0.610 |
Why?
| | Medical Errors | 1 | 2019 | 86 | 0.600 |
Why?
| | Craniocerebral Trauma | 1 | 2019 | 132 | 0.570 |
Why?
| | Infant | 18 | 2022 | 7922 | 0.570 |
Why?
| | Child | 20 | 2023 | 18340 | 0.540 |
Why?
| | Hospital Rapid Response Team | 1 | 2016 | 15 | 0.540 |
Why?
| | Sclerosing Solutions | 1 | 2016 | 9 | 0.530 |
Why?
| | Patient Safety | 1 | 2019 | 272 | 0.520 |
Why?
| | Veins | 1 | 2016 | 55 | 0.510 |
Why?
| | Bevacizumab | 1 | 2016 | 113 | 0.510 |
Why?
| | Interferon-alpha | 1 | 2016 | 184 | 0.480 |
Why?
| | Ileal Diseases | 1 | 2014 | 9 | 0.470 |
Why?
| | Child Abuse | 1 | 2019 | 455 | 0.450 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 480 | 0.440 |
Why?
| | Infant, Newborn | 14 | 2022 | 5032 | 0.440 |
Why?
| | Rectum | 2 | 2015 | 151 | 0.440 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2530 | 0.430 |
Why?
| | Receptors, Somatotropin | 1 | 2012 | 8 | 0.400 |
Why?
| | Blood Transfusion | 4 | 2022 | 265 | 0.400 |
Why?
| | Patients | 2 | 2023 | 162 | 0.380 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 557 | 0.380 |
Why?
| | Disease Management | 1 | 2015 | 554 | 0.380 |
Why?
| | Genital Neoplasms, Male | 1 | 2011 | 5 | 0.380 |
Why?
| | Crohn Disease | 1 | 2014 | 196 | 0.370 |
Why?
| | Genitalia, Male | 1 | 2011 | 10 | 0.370 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 15 | 0.370 |
Why?
| | Registries | 3 | 2015 | 1762 | 0.370 |
Why?
| | Child, Preschool | 13 | 2019 | 9093 | 0.370 |
Why?
| | Receptors, Androgen | 1 | 2012 | 131 | 0.360 |
Why?
| | Blood Vessels | 1 | 2012 | 179 | 0.350 |
Why?
| | Mesenteric Veins | 1 | 2010 | 9 | 0.350 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 178 | 0.350 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 319 | 0.340 |
Why?
| | HELLP Syndrome | 1 | 2009 | 6 | 0.340 |
Why?
| | Neoplasms | 1 | 2023 | 2082 | 0.330 |
Why?
| | Portal Vein | 1 | 2010 | 75 | 0.330 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 371 | 0.330 |
Why?
| | Adolescent | 13 | 2023 | 17724 | 0.330 |
Why?
| | Humans | 35 | 2023 | 113531 | 0.330 |
Why?
| | Venous Thrombosis | 1 | 2010 | 142 | 0.300 |
Why?
| | Retrospective Studies | 13 | 2022 | 12504 | 0.290 |
Why?
| | Bone Transplantation | 3 | 2012 | 97 | 0.260 |
Why?
| | Anticoagulants | 1 | 2010 | 548 | 0.260 |
Why?
| | Hemorrhage | 1 | 2009 | 599 | 0.250 |
Why?
| | Recurrence | 2 | 2018 | 925 | 0.230 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1465 | 0.220 |
Why?
| | Phlebography | 2 | 2016 | 35 | 0.220 |
Why?
| | Treatment Outcome | 7 | 2018 | 9006 | 0.220 |
Why?
| | Craniotomy | 3 | 2012 | 66 | 0.210 |
Why?
| | Lymphedema | 2 | 2014 | 20 | 0.200 |
Why?
| | Male | 21 | 2018 | 55112 | 0.200 |
Why?
| | Ascites | 1 | 2022 | 32 | 0.200 |
Why?
| | Mosaicism | 1 | 2022 | 62 | 0.200 |
Why?
| | Radiologists | 1 | 2022 | 35 | 0.200 |
Why?
| | Noonan Syndrome | 1 | 2022 | 17 | 0.200 |
Why?
| | Frontal Bone | 2 | 2012 | 12 | 0.190 |
Why?
| | Parietal Bone | 2 | 2012 | 11 | 0.190 |
Why?
| | Incidence | 4 | 2022 | 2310 | 0.190 |
Why?
| | Drainage | 1 | 2022 | 145 | 0.190 |
Why?
| | Congenital Abnormalities | 1 | 2022 | 72 | 0.190 |
Why?
| | Rabbits | 4 | 2016 | 713 | 0.180 |
Why?
| | Professional Role | 1 | 2022 | 148 | 0.180 |
Why?
| | Female | 18 | 2018 | 59115 | 0.180 |
Why?
| | Surgical Wound Infection | 1 | 2023 | 247 | 0.170 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 280 | 0.160 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.160 |
Why?
| | Skin Neoplasms | 2 | 2016 | 755 | 0.160 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 14 | 0.150 |
Why?
| | Duodenal Obstruction | 1 | 2018 | 5 | 0.150 |
Why?
| | Duodenostomy | 1 | 2018 | 5 | 0.150 |
Why?
| | Risk Factors | 4 | 2023 | 8606 | 0.150 |
Why?
| | Duodenum | 1 | 2018 | 62 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4384 | 0.150 |
Why?
| | Thoracotomy | 1 | 2018 | 72 | 0.150 |
Why?
| | Thoracic Injuries | 1 | 2018 | 54 | 0.140 |
Why?
| | Shock, Hemorrhagic | 1 | 2019 | 152 | 0.140 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 120 | 0.140 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2016 | 12 | 0.130 |
Why?
| | Risk Assessment | 3 | 2015 | 2953 | 0.130 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 52 | 0.130 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 13 | 0.120 |
Why?
| | Shock | 1 | 2016 | 83 | 0.120 |
Why?
| | Drug Carriers | 1 | 2016 | 110 | 0.120 |
Why?
| | Pyloric Stenosis, Hypertrophic | 1 | 2015 | 8 | 0.120 |
Why?
| | Hypotension | 1 | 2016 | 115 | 0.120 |
Why?
| | Catheters, Indwelling | 1 | 2015 | 75 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2022 | 674 | 0.120 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 212 | 0.120 |
Why?
| | Genital Diseases, Male | 1 | 2014 | 15 | 0.120 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2014 | 27 | 0.110 |
Why?
| | Scrotum | 1 | 2014 | 23 | 0.110 |
Why?
| | Penis | 1 | 2014 | 37 | 0.110 |
Why?
| | Laparoscopy | 1 | 2018 | 393 | 0.110 |
Why?
| | Peritoneal Dialysis | 1 | 2015 | 87 | 0.110 |
Why?
| | Hirschsprung Disease | 1 | 2015 | 90 | 0.110 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 91 | 0.110 |
Why?
| | Neonatal Screening | 1 | 2015 | 151 | 0.110 |
Why?
| | Postoperative Care | 1 | 2015 | 224 | 0.110 |
Why?
| | Gastroenterology | 1 | 2015 | 159 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1214 | 0.100 |
Why?
| | Global Health | 1 | 2015 | 287 | 0.100 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 175 | 0.100 |
Why?
| | Young Adult | 6 | 2015 | 10400 | 0.100 |
Why?
| | Prospective Studies | 3 | 2012 | 6189 | 0.100 |
Why?
| | Arteriovenous Malformations | 1 | 2012 | 24 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1822 | 0.100 |
Why?
| | Bone Resorption | 1 | 2012 | 72 | 0.100 |
Why?
| | Hamartoma | 1 | 2012 | 20 | 0.100 |
Why?
| | Lipomatosis | 1 | 2011 | 3 | 0.100 |
Why?
| | Biomarkers | 2 | 2012 | 3389 | 0.100 |
Why?
| | Cheek | 1 | 2011 | 16 | 0.100 |
Why?
| | Hemangioendothelioma | 1 | 2011 | 12 | 0.100 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 54 | 0.100 |
Why?
| | alpha-Fetoproteins | 1 | 2011 | 31 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 1872 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4593 | 0.090 |
Why?
| | Rare Diseases | 1 | 2011 | 85 | 0.090 |
Why?
| | Length of Stay | 1 | 2015 | 963 | 0.090 |
Why?
| | Ligation | 1 | 2010 | 74 | 0.090 |
Why?
| | Skull | 1 | 2010 | 115 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 134 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2016 | 3470 | 0.080 |
Why?
| | Osteogenesis | 1 | 2010 | 180 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1114 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1604 | 0.070 |
Why?
| | Pediatrics | 1 | 2015 | 981 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1815 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3013 | 0.070 |
Why?
| | Colorado | 1 | 2016 | 4061 | 0.070 |
Why?
| | Adult | 4 | 2012 | 30245 | 0.070 |
Why?
| | United States | 1 | 2022 | 12137 | 0.070 |
Why?
| | Databases, Factual | 1 | 2011 | 1127 | 0.070 |
Why?
| | Massachusetts | 2 | 2014 | 134 | 0.060 |
Why?
| | Liver | 1 | 2011 | 1630 | 0.050 |
Why?
| | Prognosis | 1 | 2011 | 3318 | 0.050 |
Why?
| | Splenectomy | 1 | 2022 | 51 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 47 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 112 | 0.050 |
Why?
| | Esophageal Atresia | 1 | 2022 | 23 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 227 | 0.050 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 30 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2022 | 88 | 0.050 |
Why?
| | X-Ray Microtomography | 2 | 2012 | 73 | 0.050 |
Why?
| | Animals | 4 | 2016 | 31162 | 0.050 |
Why?
| | Pyridones | 1 | 2022 | 122 | 0.050 |
Why?
| | Survival Rate | 2 | 2015 | 1634 | 0.050 |
Why?
| | Spleen | 1 | 2022 | 480 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 384 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 781 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 3313 | 0.040 |
Why?
| | Heart Diseases | 1 | 2022 | 327 | 0.040 |
Why?
| | Middle Aged | 3 | 2014 | 26552 | 0.040 |
Why?
| | Pregnancy | 1 | 2009 | 5490 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 107 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 131 | 0.040 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 29 | 0.030 |
Why?
| | Resuscitation | 1 | 2018 | 221 | 0.030 |
Why?
| | Dialysis Solutions | 1 | 2015 | 21 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1682 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 141 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 75 | 0.030 |
Why?
| | Constipation | 1 | 2015 | 75 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 314 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 175 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 123 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 216 | 0.030 |
Why?
| | Heart Arrest | 1 | 2018 | 293 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2016 | 468 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 231 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 2015 | 157 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 247 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 275 | 0.030 |
Why?
| | Gestational Age | 1 | 2015 | 762 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 809 | 0.030 |
Why?
| | Biopsy | 1 | 2015 | 1024 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1421 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1159 | 0.020 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2011 | 13 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 55 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 383 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1443 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2011 | 74 | 0.020 |
Why?
| | Osseointegration | 1 | 2011 | 37 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1832 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 85 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 67 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1783 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 114 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 486 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 326 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 2875 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 914 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 310 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 248 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 735 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 676 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 794 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 496 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 4880 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 6032 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2293 | 0.010 |
Why?
| | Aged | 1 | 2014 | 18944 | 0.010 |
Why?
|
|
Kulungowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|